FDA Approves Mylan and Biocon’s Fulphila (pegfilgrastim-jmdb), the First Biosimilar to Neulasta Read more
Merck’s KEYTRUDA (pembrolizumab) Showed Overall Response Rate of Nearly 40 Percent as First-Line Therapy Read more
Third Novartis Phase III trial shows Kisqali combination therapy significantly improves PFS in HR+/HER2- advanced breast cancer Read more
EC approves Roche’s Perjeta for post-surgery treatment of HER2-positive early breast cancer at high risk of recurrence Read more
Alcami to Become Industry Leading Platform CDMO Following Acquisition by Madison Dearborn Partners Read more
PPD and NeoGenomics Forming Global Strategic Alliance for Pathology and Molecular Testing Solutions Read more
Pharmaceutical Microbiology West Coast Conference & Exhibition takes place in less than a week Read more
Aptar Pharma and Propeller Health Partner to Develop Digital Medicine Platform Across Therapeutic Areas Read more